BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)


**Appendix 5.**

**Biectoorbitale breadth**

| Study or Subgroup | Male Mean | Male SD | Male Total | Female Mean | Female SD | Female Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Kim et al. 2003 | 131.1 | 9.6 | 70 | 119.3 | 6.6 | 40 | 31.7% | 11.80 [8.76, 14.84] |
| Oestenstad and Perkins 1992 | 127 | 6 | 38 | 119 | 6 | 30 | 35.5% | 8.00 [5.13, 10.87] |
| Oestenstad et al. 2007 | 115.9 | 7.2 | 21 | 107.6 | 6.2 | 20 | 17.4% | 8.30 [4.19, 12.41] |
| Oestenstad et al. 2010 | 115.3 | 7.2 | 21 | 107.3 | 7 | 20 | 15.5% | 8.00 [3.65, 12.35] |
| **Total (95% CI)** | | | **150** | | | **110** | **100.0%** | **9.26 [7.54, 10.97]** |

Heterogeneity: $Chi^2 = 3.95$, df = 3 (P = 0.27); $I^2 = 24\%$
Test for overall effect: Z = 10.60 (P < 0.00001)




**Bizygomatic breadth [Face width]**

| Study or Subgroup | Male Mean | Male SD | Male Total | Female Mean | Female SD | Female Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Brazile et al. 1998 | 136 | 8 | 91 | 129 | 12 | 95 | 6.3% | 7.00 [4.08, 9.92] |
| De-Ynigo-Mojado et al. 2021 | 139.02 | 7.17 | 37 | 129.56 | 6.17 | 37 | 5.8% | 9.46 [6.41, 12.51] |
| Fakherpour et al. 2020 | 120.16 | 10.92 | 25 | 124.92 | 10.32 | 37 | 1.8% | -4.76 [-10.18, 0.66] |
| Gross and Horstman 1990 | 140.6 | 6.4 | 61 | 130.1 | 5.7 | 60 | 11.5% | 10.50 [8.34, 12.66] |
| Han and Choi 2003 | 132 | 9 | 112 | 122 | 7 | 38 | 6.9% | 10.00 [7.22, 12.78] |
| Honarbakhsh et al. 2018 | 119.36 | 12.36 | 95 | 117.4 | 11.01 | 189 | 6.2% | 1.96 [-0.98, 4.90] |
| Kim et al. 2003 | 147.6 | 5 | 70 | 136.6 | 4.9 | 40 | 14.6% | 11.00 [9.08, 12.92] |
| Kim et al. 2015 | 138.6 | 8.1 | 16 | 131.6 | 6 | 33 | 2.7% | 7.00 [2.53, 11.47] |
| Lin et al. 2017 | 128.2 | 6.6 | 101 | 122.7 | 7 | 105 | 15.6% | 5.50 [3.64, 7.36] |
| Oestenstad and Perkins 1992 | 139 | 8 | 38 | 129 | 6 | 30 | 4.8% | 10.00 [6.67, 13.33] |
| Oestenstad et al. 2007 | 137.5 | 4.8 | 21 | 129.6 | 7 | 20 | 3.9% | 7.90 [4.21, 11.59] |
| Oestenstad et al. 2010 | 136.8 | 4.8 | 21 | 129.8 | 7.7 | 20 | 3.4% | 7.00 [3.05, 10.95] |
| Spies et al. 2011 | 150.3 | 6.6 | 14 | 141.9 | 7.9 | 15 | 1.9% | 8.40 [3.11, 13.69] |
| Yu et al. 2014 | 146.1 | 5.8 | 26 | 138.9 | 5.2 | 24 | 5.8% | 7.20 [4.15, 10.25] |
| Zhuang et al. 2005 | 69.1 | 3 | 14 | 65.1 | 4.2 | 18 | 8.6% | 4.00 [1.50, 6.50] |
| **Total (95% CI)** | | | **742** | | | **761** | **100.0%** | **7.54 [6.80, 8.27]** |

Heterogeneity: $Chi^2 = 72.78$, df = 14 (P < 0.00001); $I^2 = 81\%$
Test for overall effect: Z = 20.16 (P < 0.00001)